COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Schett, Georg; Sticherling, Michael; Neurath, Markus F

Schett, Georg; Sticherling, Michael; Neurath, Markus F.

Schett G; Department of Internal Medicine 3, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany. georg.schett@uk-erlangen.de.
Sticherling M; Deutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany. georg.schett@uk-erlangen.de.
Neurath MF; Deutsches Zentrum fuer Immuntherapie (DZI), FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany.

Nat Rev Immunol ; 20(5): 271-272, 2020 05.

Article in English | MEDLINE | ID: covidwho-66248

Subject(s)

Coronavirus Infections/complications; Cytokines/antagonists & inhibitors; Immune System Diseases/complications; Pneumonia, Viral/complications; COVID-19; Coronavirus Infections/drug therapy; Coronavirus Infections/immunology; Cytokines/immunology; Humans; Inflammation/complications; Pandemics; Pneumonia, Viral/drug therapy; Pneumonia, Viral/immunology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Cytokines / Coronavirus Infections / Immune System Diseases Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Nat Rev Immunol Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: S41577-020-0312-7

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google